Biomarkers to Pinpoint Hidradenitis Suppurativa Inch Forward Biomarkers to Pinpoint Hidradenitis Suppurativa Inch Forward
A lack of physician familiarity with the uncommon inflammatory skin condition points to a need for diagnostic biomarkers, experts say.Medscape Medical News
Conclusions: We have comprehensively explored on HS ’s possible effect on the QOL of the affected individuals and identified a 23-item HS-specific QOL questionnaire. The questionnaire proved to be feasible, acceptable, and comprehensible in the second round of pilot testing. With HiSQOL, researchers can measure HS-specific QOL in future clinical tr ials, potentially enabling them to discover more effective treatment options. It is envisaged, that after thorough validation in a trial setting, a streamlined version of HISQOL may also become available for clinical use in daily practice.Skin Appendage Disord
Multiple step-by-step surgeries in place of a major procedure to remove diseased skin related to hidradenitis suppurativa can eliminate the need for skin grafts, a small pilot study shows.Medscape Medical News
The combination of methotrexate and anti-TNF therapy can improve clinical response in patients with severe hidradenitis suppurativa, first results from a new study demonstrate.Medscape Medical News
Here, we report a case of neutrophilic eccrine hidradenitis (NEH) in a teenage male with synovial sarcoma associated with extracutaneous manifestations including myositis and splenomegaly secondary to pegfilgrastim. To the best of our knowledge, NEH has not been previously reported to occur in association with extracutaneous manifestations. Key Clinical MessageHere, we report a case of neutrophilic eccrine hidradenitis (NEH) in a teenage male with synovial sarcoma associated with extracutaneous manifestations including myositis and splenomegaly secondary to pegfilgrastim. To the best of our knowledge, NEH has not been prev...
Hidradenitis suppurativa (HS) and pyoderma gangrenosum (PG) are reported to coexist, although prevalence of PG among HS patients has not been systematically evaluated.
CONCLUSION: The very wide intervals for limits of agreement imply that substantial changes are needed in clinical research in order to rule out measurement error. The results illustrate a difficulty, even for experienced HS-experts, to agree on the type and number of lesions when evaluating disease severity. The apparent caveats call for global efforts, such as the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) to reach consensus on how valid HS physical signs are best measured reliably in randomised trials. This article is protected by copyright. All rights reserved. PMID: 30724351 ...
Condition: Hidradenitis Suppurativa Interventions: Drug: CFZ533; Drug: Placebo to CFZ533; Drug: LYS006; Drug: Placebo to LYS006 Sponsor: Novartis Pharmaceuticals Not yet recruiting